Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial)-Reference-Cited by-同舟云学术

Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial)

Published:2018-11-12 Issue:4 Volume:24 Page:445-453
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Fujisawa Shin,Ueda Yasunori,Usuki Kensuke,Kobayashi Hajime,Kondo Eisei,Doki Noriko,Nakao Takafumi,Kanda Yoshinobu,Kosugi Nobuharu,Kosugi Hiroshi,Kumagai Takashi,Harada Hiroshi,Shikami Masato,Maeda Yasuhiro,Sakura Toru,Inokuchi Koiti,Saito Akio,Nawa Yuichiro,Ogasawara Masahiro,Nishida Junji,Kondo Takeshi,Yoshida Chikashi,Kuroda Hiroyuki,Tabe Yoko,Maeda Yoshinobu,Imajo Kenji,Kojima Kensuke,Morita Satoshi,Komukai Sho,Kawaguchi Atsushi,Sakamoto Junichi,Kimura Shinya

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

http://link.springer.com/content/pdf/10.1007/s10147-018-1368-2.pdf

Reference26 articles.

1. Bower H, Bjorkholm M, Dickman PW et al (2016) Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol 34:2851–2857

2. Hamilton A, Helgason GV, Schemionek M et al (2012) Chronic myeloid leukemia stem cells are not dependent on BCR-ABL kinase activity for their survival. Blood 119:1501–1510

3. Mahon FX, Rea D, Guilhot J et al (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre stop imatinib (STIM) trial. Lancet Oncol 11:1029–1035

4. Etienne G, Guilhot J, Rea D et al (2017) Long-term follow-up of the French stop imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol 35:298–305

5. Takahashi N, Tauchi T, Kitamura K et al (2018) Deeper molecular response is a predictive factor for treatment–free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG–STIM213 study. Int J Hematol 107:185–193

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discontinuation of Tyrosine Kinase Inhibitor Therapy and Treatment Free Remission (TFR) in Chronic Myeloid Leukemia: Successful Achievement of TFR in More Than Two-Third of Patients in a Real-World Practice;Clinical Lymphoma Myeloma and Leukemia;2024-08

2. Treatment-Free Remission in Chronic Myeloid Leukemia;Journal of Clinical Medicine;2024-04-27

3. KIR3DL1-HLA-Bw status in CML is associated with achievement of TFR: the POKSTIC trial, a multicenter observational study;Blood Neoplasia;2024-03

4. BCR-ABL kinase domain mutations in CML patients, experience from a tertiary care center in North India;Leukemia Research Reports;2024

5. Long-term Results of Imatinib Discontinuation in Patients with Chronic-phase Chronic Myeloid Leukemia: A National Multicenter Prospective Study;Turkish Journal of Hematology;2023-12-28